Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial
Authors' conclusion
Empagliflozin, compared with once-weekly dulaglutide switched from DPP4-i, demonstrated greater HbA1c reduction and weight loss in patients with T2D inadequately controlled with metformin, sulfonylurea, and DPP4-i.
Study context
- Population
- Patients with T2D and HbA1c ≥7.5% (58 mmol/mol) on metformin, sulfonylurea and DPP4-i
- Participants
- 152 patients
- Comparison
- Daily empagliflozin add-on vs once-weekly dulaglutide switched from DPP4-i
- Empagliflozinn = 76
- Dulaglutiden = 76reference
- Primary endpoint
- Change from baseline HbA1c
- Follow-up
- 24 weeks
Methodological detailsmulticentre, 24-week
- Multicentre
- 24-week
Primary result
As reported in the abstract
Change in HbA1c from baseline · week 24
Each group vs dulaglutideMean treatment difference, % (95% CI)P value
Empagliflozin
−0.27(−0.50 to −0.04)
P = 0.024Each group vs dulaglutideMean treatment difference, mmol/mol (95% CI)P value
Empagliflozin
−2.88(−5.37 to −0.39)
P = 0.024Further findings
Body weight change from baseline with empagliflozin · week 24
- Empagliflozin significantly reduced body weight from baseline
- −1.72 kg (95% CI −1.98 to −0.59, p < 0.001)
Safety
Events
| Outcome | Empagliflozin | Dulaglutide |
|---|---|---|
| Serious adverse events | 0 | 0 |
Original publication
Glucometabolic control of once-weekly dulaglutide switched from DPP4 inhibitor versus daily empagliflozin add-on in patients with type 2 diabetes inadequately controlled with metformin, sulfonylurea, and DPP4 inhibitor: A randomised trial. Diabetes Res Clin Pract. Published 16 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →